Five-year follow-up results from the phase III CLL14 trial demonstrated that over 60% of patients with previously untreated chronic lymphocytic leukemia who had received one-year fixed-duration combination treatment of Venclyxto/Venclexta (venetoclax) plus Gazyva (obinutuzumab) continued to show longer progression-free survival and higher rates of undetectable minimal residual disease after four years off treatment.
J. Leonard Lichtenfeld joined SpotitEarly, an Israel-based technology company transforming cancer screening by harnessing the power of artificial intelligence and dogs to detect cancer early, as chief medical officer.
